455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Nektar Therapeutics Enters $150 Million Equity Distribution Agreement
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Announces Pricing of Upsized $325 Million Public Offering
Nektar Therapeutics Reports $741.7 Million in Cash and Investments
Reg. FD, Other Events
Reports Fourth Quarter and Full Year 2025 Financial Results
Announces Pricing of Upsized $400 Million Public Offering
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report